

## Management of acute asthma in children in emergency department

# Annex 6

### Age 2-5 years

#### ASSESS ASTHMA SEVERITY

##### Moderate asthma

- SpO<sub>2</sub> ≥92%
- No clinical features of severe asthma

**NB: If a patient has signs and symptoms across categories, always treat according to their most severe features**

##### Severe asthma

- SpO<sub>2</sub> <92%
- Too breathless to talk or eat
- Heart rate >140/min
- Respiratory rate >40/min
- Use of accessory neck muscles

##### Life-threatening asthma

- SpO<sub>2</sub> <92% plus any of:
  - Silent chest
  - Poor respiratory effort
  - Agitation
  - Altered consciousness
  - Cyanosis

Oxygen via face mask/nasal prongs to achieve SpO<sub>2</sub> 94-98%

- β<sub>2</sub> agonist 2-10 puffs via spacer ± facemask (given one puff at a time inhaled separately using tidal breathing)
- Give one puff of β<sub>2</sub> agonist every 30-60 seconds up to 10 puffs according to response
- Consider soluble oral prednisolone 20 mg

Reassess within 1 hour

- β<sub>2</sub> agonist 10 puffs via spacer ± facemask or nebulised salbutamol 2.5 mg
- Soluble prednisolone 20 mg or IV hydrocortisone 4 mg/kg
- If poor response add 0.25 mg nebulised ipratropium bromide**
- Repeat β<sub>2</sub> agonist and ipratropium up to every 20 minutes for 2 hours according to response

- Nebulised β<sub>2</sub> agonist: salbutamol 2.5 mg **plus** ipratropium bromide 0.25 mg nebulised
- Oral prednisolone 20 mg or IV Hydrocortisone 4 mg/kg if vomiting
- Discuss with senior clinician, PICU team or paediatrician**
- Repeat bronchodilators every 20-30 minutes

#### DISCHARGE PLAN

- Continue β<sub>2</sub> agonist 4 hourly as necessary
- Consider prednisolone 20 mg daily for up to 3 days
- Advise to contact GP if not controlled on above treatment
- Provide a written asthma action plan
- Review regular treatment
- Check inhaler technique
- Arrange GP follow up

Arrange immediate transfer to PICU/HDU if poor response to treatment

Admit all cases if features of severe exacerbation persist after initial treatment

### Age >5 years

#### ASSESS ASTHMA SEVERITY

##### Moderate asthma

- SpO<sub>2</sub> ≥92%
- PEF ≥50% best or predicted
- No clinical features of severe asthma

**NB: If a patient has signs and symptoms across categories, always treat according to their most severe features**

##### Severe asthma

- SpO<sub>2</sub> <92%
- PEF 33-50% best or predicted
- Heart rate >125/min
- Respiratory rate >30/min
- Use of accessory neck muscles

##### Life-threatening asthma

- SpO<sub>2</sub> <92% plus any of:
  - PEF <33% best or predicted
  - Silent chest
  - Poor respiratory effort
  - Altered consciousness
  - Cyanosis

Oxygen via face mask/nasal prongs to achieve SpO<sub>2</sub> 94-98%

- β<sub>2</sub> agonist 2-10 puffs via spacer and mouthpiece (given one puff at a time inhaled separately using tidal breathing)
- Give one puff of β<sub>2</sub> agonist every 30-60 seconds up to 10 puffs according to response
- Oral prednisolone 30-40 mg

Reassess within 1 hour

- β<sub>2</sub> agonist 10 puffs via spacer or nebulised salbutamol 5 mg
- Oral prednisolone 30-40 mg or IV hydrocortisone 4 mg/kg if vomiting
- If poor response add 0.25 mg nebulised ipratropium bromide**
- Repeat β<sub>2</sub> agonist and ipratropium up to every 20 minutes for 2 hours according to response

- Nebulised β<sub>2</sub> agonist: salbutamol 5 mg **plus** ipratropium bromide 0.25 mg nebulised
- Oral prednisolone 30-40 mg or IV Hydrocortisone 4 mg/kg if vomiting
- Discuss with senior clinician, PICU team or paediatrician**
- Repeat bronchodilators every 20-30 minutes

#### DISCHARGE PLAN

- Continue β<sub>2</sub> agonist 4 hourly as necessary
- Consider prednisolone 30-40 mg daily for up to 3 days
- Seek medical advice if not controlled on above treatment
- Provide a written asthma action plan
- Review regular treatment
- Check inhaler technique
- Arrange GP follow up

Arrange immediate transfer to PICU/HDU if poor response to treatment

Admit all cases if features of severe exacerbation persist after initial treatment



**MEDICAL ASSESSMENT**

A&E DR

PAEDIATRIC DR

Other: \_\_\_\_\_

SEEN BY: \_\_\_\_\_

SIGNATURE: \_\_\_\_\_

TIME: \_\_\_\_\_

**HISTORY**

		With exercise	Day	Night	Night wakening
<u>Chronic symptoms</u>	Cough:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	Wheeze:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	Shortness of breath on exertion (S.O.B.):	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

With this attack

	Cough:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	Wheeze:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	S.O.B. on exertion:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**IN THE LAST YEAR**

Number of A&E asthma/wheeze attendances:

Number of admissions with asthma/wheeze:

Number of courses of antibiotics for chest infections:

Number of courses of oral steroids

Currently attend hospital clinic? Y  N

Currently attend GP for asthma? Y  N

**TRIGGERS / OTHER POINTS IN HISTORY**

---

---

---

---

---

---

---

---

**USUAL MEDICINES**

Drug	Dose	Frequency	Route / Device	Delivery System
<b>Reliever:</b>				
<b>Preventer (s):</b>				
<b>Other:</b>				

**EXAMINATION**

1. Breathlessness: Not breathless  Breathless on exercise  Breathless at rest  Exhausted
2. Able to speak/babble: Easily  With difficulty  Only short sentences  Unable
3. Use of accessory muscles: No  Yes

Chest auscultation / rest of examination positive findings

---

---

---

---

---

---

---

---

**DIAGNOSIS / ADDITIONAL MEDICAL NOTES**

---

---

---

---

---

---

---

---

**MANAGEMENT: Note if under 2 years of age or moderate or severe - discuss with middle grade**

<b>Doses of systemic steroids:</b> Prednisolone (oral, once daily for a minimum of 3 days) <b>OR</b> Hydrocortisone (IV six hourly)	<2 years	2-5 years	> 5 years
	10mg 25mg	20mg 50mg	30-40mg 100mg

MILD / MODERATE	SEVERE
<ul style="list-style-type: none"> <li>B<sub>2</sub> agonist 2-10 puffs via spacer</li> <li>Reassess after 15 minutes</li> </ul> <p><i>If responds:</i></p> <ul style="list-style-type: none"> <li>Continue inhaled B<sub>2</sub> agonist 1-4 hourly</li> <li>Consider adding systemic steroid as above</li> <li>Home discharge criteria (see next page)</li> </ul> <p><i>If not responding:</i></p> <ul style="list-style-type: none"> <li>Give second dose B<sub>2</sub> agonist</li> <li>Give systemic steroid as above</li> <li>Admit to Short Stay Ward (SSW) / hospital</li> </ul> <p>NB: IF POOR RESPONSE TO SECOND DOSE B<sub>2</sub> AGONIST TREAT AS SEVERE</p>	<ul style="list-style-type: none"> <li>Nebulised B<sub>2</sub> agonist with oxygen as driving gas &lt; 5 yrs 2.5mg Salbutamol or 5mg Terbutaline &gt; 5 yrs 5 mg Salbutamol or 10mg Terbutaline</li> <li>Continue O<sub>2</sub> via face mask / nasal prongs</li> <li>Systemic steroids as above</li> <li><i>If responds:</i> continue nebulised B<sub>2</sub> agonist, (doses can be repeated every 20-30 minutes)</li> <li>Arrange admission</li> <li><i>If not responding:</i> give second dose nebulised B<sub>2</sub> agonist immediately</li> </ul> <p><i>If still not responding: TREAT AS LIFE THREATENING</i></p>

**LIFE THREATENING – TREAT AS SEVERE PLUS THE FOLLOWING:**

- Discuss with senior clinician (consultant, PICU team or paediatric team)
- Consider CXR and blood gases
- Nebulised B<sub>2</sub> agonist and nebulised Ipratropium bromide 250 micrograms, mixed together (can be repeated every 20 – 30 minutes)
- Bolus of 5mg / kg aminophylline over 20 minutes followed by an infusion of 0.9mg /kg/hr (in 0.9% sodium chloride or 5% dextrose) (As per Roberts G, Thorax, 2003; 58:306-310 which supersedes earlier 2003 BTS Guidelines)

NB: ARRANGE IMMEDIATE TRANSFER TO PICU/HDU IF POOR RESPONSE TO TREATMENT.  
 ADMIT ALL CASES IF FEATURES OF SEVERE EXACERBATION PERSIST AFTER INITIAL TREATMENT  
 (AS PER ANNEX 6 OF BTS GUIDELINES 2003).  
 (PROTOCOLS AVAILABLE FOR IV SALBUTAMOL & IV MAGNESIUM; CONSULTANT DECISION)

**PRESCRIBED DRUGS & ADMINISTRATION**

PRESCRIBED DRUGS & ADMINISTRATION					WEIGHT:	Kg	
Date	Time	Drug	Dose	Route / Device	Prescribers Signature	Administered by Signature	Time

**CLINICAL ASSESSMENT**

After treatment	1 <sup>st</sup> Bronchodilator	2 <sup>nd</sup> Bronchodilator	3 <sup>rd</sup> Bronchodilator	4 <sup>th</sup> Bronchodilator			
	Time:	Time:	Time:	Time:			
Pulse							
Respirations							
SA 02							
PFR	Pre:						
PFR	Post: (15mins)						
Temp	If initial temp >37.5 repeat hourly	Time:	Time:	Time:	Time:	Time:	Time:
		Temp:	Temp:	Temp:	Temp:	Temp:	Temp:

**INVESTIGATIONS / RESULTS - IF DONE:**

Chest X-Ray:  \_\_\_\_\_

Bloods:  \_\_\_\_\_

Other:  \_\_\_\_\_



# PAEDIATRIC NORMAL VALUES

## PEAK EXPIRATORY FLOW RATE

For use with EU / EN13826 scale PEF meters only

Height (m)	Height (ft)	Predicted EU PEFR (L/min)	Height (m)	Height (ft)	Predicted EU PEFR (L/min)
0.85	2'9"	87	1.30	4'3"	212
0.90	2'11"	95	1.35	4'5"	233
0.95	3'1"	104	1.40	4'7"	254
1.00	3'3"	115	1.45	4'9"	276
1.05	3'5"	127	1.50	4'11"	299
1.10	3'7"	141	1.55	5'1"	323
1.15	3'9"	157	1.60	5'3"	346
1.20	3'11"	174	1.65	5'5"	370
1.25	4'1"	192	1.70	5'7"	393

Normal PEF values in children correlate best with height; with increasing age, larger differences occur between the sexes. These predicted values are based on the formulae given in Lung Function by J.E.

Cotes (Fourth Edition), adapted for EU scale Mini-Wright peak flow meters by Clement Clarke.

Date of preparation – 7th October 2004



Mini-Wright (Standard Range) EU scale  
Blue text on a yellow background

Single Patient Use: Part Ref: 3103388  
Multiple Patient Use: Part Ref: 3103387  
NHS Logistics Code: FDD 609



Mini-Wright (Low Range) EU scale  
Blue text on a yellow background

Single Patient use: Part Ref: 3104708  
Multiple Patient Use: Part Ref: 3104710


For more information, visit the website [www.peakflow.com](http://www.peakflow.com)



Precision by Tradition

Clement Clarke International Ltd. Edinburgh Way, Harlow, Essex. England CM20 2TT U.K.  
Tel. +44 (0) 1279 414969 Fax. +44 (0) 1279 456304 [www.peakflow.com](http://www.peakflow.com) email: [resp@clement-clarke.com](mailto:resp@clement-clarke.com)

# Annex 10



Adapted by Clement Clarke for use with EN13826 / EU scale peak flow meters from Nunn AJ Gregg I, Br Med J 1989:298;1068-70